American Radiology Services, Johns Hopkins Green Spring, 10755 Falls Rd, Suite 440, Lutherville, MD 21093, USA.
Radiology. 2010 Jan;254(1):79-87. doi: 10.1148/radiol.2541090953.
To determine reasons for nonparticipation in a trial of supplemental screening with magnetic resonance (MR) imaging after mammography and ultrasonography (US).
Women(n = 2809) at elevated risk of breast cancer were enrolled in the American College of Radiology Imaging Network 6666 US Screening Protocol at 21 institutions. Fourteen institutions met technical and experience requirements for this institutional review board-approved, HIPAA-compliant substudy of supplemental screening with MR imaging. Those women who had completed 0-, 12-, and 24-month screenings with mammography combined with US were considered for a single contrast material-enhanced MR examination within 8 weeks after completing the 24-month mammography-US screening. A total of 1593 women had complete MR substudy registration data: 378 of them were ineligible for the study, and 1215 had analyzable data. Reasons for nonparticipation were determined. Demographic data were compared between study participants and nonparticipants.
Of 1215 women with analyzable data, 703 (57.9%), with a mean age of 54.8 years, were enrolled in the MR substudy and 512 (42.1%) declined participation. Women with a 25% or greater lifetime risk of breast cancer were more likely to participate (odds ratio, 1.53; 95% confidence interval: 1.10, 2.12). Of 512 nonparticipants, 130 (25.4%) refused owing to claustrophobia; 93 (18.2%), owing to time constraints; 62 (12.1%), owing to financial concerns; 47 (9.2%), because their physician would not provide a referral and/or did not believe MR imaging was indicated; 40 (7.8%), because they were not interested; 39 (7.6%), because they were medically intolerant to MR imaging; 29 (5.7%), because they did not want to undergo intravenous injection; 27 (5.3%), owing to additional biopsy or other procedures that might be required subsequently; 21 (4.1%), owing to MR imaging scheduling constraints; 11 (2.2%), because of the travel required; seven (1.4%), owing to gadolinium-related risks or allergies; and six (1.2%), for unknown reasons.
Of 1215 women with elevated breast cancer risk who could, according to protocol guidelines, undergo breast MR imaging, only 57.9% agreed to participate.
确定在乳房 X 线摄影和超声(US)联合检查后进行补充性磁共振(MR)成像筛查试验中不参与的原因。
21 家机构中的 2809 名患有乳腺癌风险升高的女性参加了美国放射学院影像学网络 6666 项美国筛查方案。14 家机构符合该机构审查委员会批准的、符合 HIPAA 规定的补充性 MR 成像筛查的技术和经验要求。在完成 24 个月的乳房 X 线摄影-US 筛查后 8 周内,对完成 0、12 和 24 个月的乳房 X 线摄影联合 US 筛查的女性进行单次对比增强 MR 检查。共有 1593 名女性完成了完整的 MR 子研究注册数据:其中 378 名不符合研究条件,1215 名具有可分析数据。确定了不参与的原因。对研究参与者和非参与者的人口统计学数据进行了比较。
在 1215 名具有可分析数据的女性中,703 名(57.9%)年龄平均为 54.8 岁,参加了 MR 子研究,512 名(42.1%)拒绝参加。终生乳腺癌风险为 25%或更高的女性更有可能参与(优势比,1.53;95%置信区间:1.10,2.12)。在 512 名不参与者中,130 名(25.4%)因幽闭恐惧症而拒绝;93 名(18.2%)因时间限制而拒绝;62 名(12.1%)因经济问题而拒绝;47 名(9.2%)因医生不会提供转介且/或认为不需要进行 MR 成像;40 名(7.8%)因不感兴趣而拒绝;39 名(7.6%)因不能耐受 MR 成像而拒绝;29 名(5.7%)因不希望进行静脉注射而拒绝;27 名(5.3%)因可能随后需要进行其他活检或其他程序而拒绝;21 名(4.1%)因 MR 成像安排限制而拒绝;11 名(2.2%)因旅行要求而拒绝;7 名(1.4%)因与钆相关的风险或过敏而拒绝;6 名(1.2%)因未知原因而拒绝。
在符合方案指南可接受乳房 MR 成像的 1215 名患有高乳腺癌风险的女性中,只有 57.9%同意参与。